REGN vs. AMGN, GILD, VRTX, ALNY, BIIB, UTHR, NBIX, INCY, BMRN, and EXEL
Should you be buying Regeneron Pharmaceuticals stock or one of its competitors? The main competitors of Regeneron Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Incyte (INCY), BioMarin Pharmaceutical (BMRN), and Exelixis (EXEL). These companies are all part of the "biotechnology" industry.
Regeneron Pharmaceuticals vs.
Regeneron Pharmaceuticals (NASDAQ:REGN) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings, analyst recommendations, media sentiment and community ranking.
In the previous week, Regeneron Pharmaceuticals had 4 more articles in the media than Amgen. MarketBeat recorded 65 mentions for Regeneron Pharmaceuticals and 61 mentions for Amgen. Amgen's average media sentiment score of 1.20 beat Regeneron Pharmaceuticals' score of 0.24 indicating that Amgen is being referred to more favorably in the news media.
83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 76.5% of Amgen shares are held by institutional investors. 7.5% of Regeneron Pharmaceuticals shares are held by company insiders. Comparatively, 0.7% of Amgen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Regeneron Pharmaceuticals has a net margin of 33.61% compared to Amgen's net margin of 13.00%. Amgen's return on equity of 168.35% beat Regeneron Pharmaceuticals' return on equity.
Amgen has higher revenue and earnings than Regeneron Pharmaceuticals. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.
Regeneron Pharmaceuticals presently has a consensus price target of $1,015.38, suggesting a potential upside of 48.97%. Amgen has a consensus price target of $314.91, suggesting a potential upside of 15.73%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Regeneron Pharmaceuticals is more favorable than Amgen.
Amgen received 5 more outperform votes than Regeneron Pharmaceuticals when rated by MarketBeat users. Likewise, 72.07% of users gave Amgen an outperform vote while only 66.97% of users gave Regeneron Pharmaceuticals an outperform vote.
Regeneron Pharmaceuticals has a beta of 0.1, meaning that its share price is 90% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500.
Summary
Regeneron Pharmaceuticals beats Amgen on 10 of the 18 factors compared between the two stocks.
Get Regeneron Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for REGN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Regeneron Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:REGN) was last updated on 1/21/2025 by MarketBeat.com Staff
Free REGN Stock Alerts